Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.

about

Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature.

P2860

Q36640837-BEF947F4-11A6-4E30-BE15-E747719B8757

P2860

Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.

Item

http://www.wikidata.org/entity/Q36110447

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Bortezomib-based treatment for ...... report and literature review.

@ast

Bortezomib-based treatment for ...... report and literature review.

@en

type

Item

label

Bortezomib-based treatment for ...... report and literature review.

@ast

Bortezomib-based treatment for ...... report and literature review.

@en

prefLabel

Bortezomib-based treatment for ...... report and literature review.

@ast

Bortezomib-based treatment for ...... report and literature review.

@en

P1476

Bortezomib-based treatment for ...... report and literature review.

@en

P2093

Chunyang Zhang

http://www.w3.org/2001/XMLSchema#string

Jian Hou

http://www.w3.org/2001/XMLSchema#string

Shuyan Liu

http://www.w3.org/2001/XMLSchema#string

Weijun Fu

http://www.w3.org/2001/XMLSchema#string

Zhengang Yuan

http://www.w3.org/2001/XMLSchema#string

P2860

PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor.

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.

Advances in the understanding and management of angioimmunoblastic T-cell lymphoma.

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation.

P304

262-264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2012.724

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230586694

http://www.w3.org/2001/XMLSchema#string

P698

22844366

http://www.w3.org/2001/XMLSchema#string

P932

3402752

http://www.w3.org/2001/XMLSchema#string

Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.

about

P2860

P2860

Bortezomib-based treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma: Case report and literature review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932